Insider Transactions in Q4 2021 at Aurinia Pharmaceuticals Inc. (AUPH)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Direct |
1,600
+23.19%
|
$32,000
$20.04 P/Share
|
|
Nov 11
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100,000
-53.39%
|
$2,800,000
$28.89 P/Share
|
|
Nov 11
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+34.81%
|
$500,000
$5.3 P/Share
|
|
Nov 11
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,000
-16.45%
|
$319,000
$29.5 P/Share
|
|
Nov 11
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
29,000
-30.25%
|
$812,000
$28.82 P/Share
|
|
Nov 11
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,000
+23.23%
|
$522,000
$18.38 P/Share
|
|
Nov 10
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100,000
-29.16%
|
$3,000,000
$30.86 P/Share
|
|
Nov 10
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+22.3%
|
$500,000
$5.68 P/Share
|
|
Nov 10
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
60,000
-26.21%
|
$1,800,000
$30.91 P/Share
|
|
Nov 09
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
50,000
-36.42%
|
$1,500,000
$30.17 P/Share
|
|
Nov 09
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-28.27%
|
$1,500,000
$30.17 P/Share
|
|
Nov 01
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
45,000
-20.28%
|
$1,395,000
$31.64 P/Share
|
|
Nov 01
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+16.86%
|
$135,000
$3.2 P/Share
|
|
Nov 01
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.68%
|
$1,395,000
$31.64 P/Share
|
|
Nov 01
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+19.8%
|
$225,000
$5.3 P/Share
|
|
Oct 25
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
130,000
-66.42%
|
$3,770,000
$29.75 P/Share
|
|
Oct 25
2021
|
Robert Bindert Huizinga EVP of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
95,000
+32.68%
|
$285,000
$3.2 P/Share
|